-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
Freeline Therapeutics Holdings plc quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from Q1 2020 to Q1 2023.
- Freeline Therapeutics Holdings plc Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending March 31, 2023 was $2.44M.
- Freeline Therapeutics Holdings plc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$102M, a 27.6% increase from 2021.
- Freeline Therapeutics Holdings plc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was -$140M, a 67% decline from 2020.
- Freeline Therapeutics Holdings plc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2020 was -$84M, a 55.3% decline from 2019.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)